TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03425981

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Whole-Body Electromyostimulation Training
Description: The WB-EMS training program consisted of six WB-EMS training sessions (one per week) and six running training sessions (also one per week).~This intervention programme followed a within-day undulating periodization model. The training sessions were divided into four parts: warm up (A), strength (B), high intensity interval power training (c), and high intensity interval training (HIIT) (D).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole-Body Electromyostimulation Training
Description: The WB-EMS training program consisted of six WB-EMS training sessions (one per week) and six running training sessions (also one per week).~This intervention programme followed a within-day undulating periodization model. The training sessions were divided into four parts: warm up (A), strength (B), high intensity interval power training (c), and high intensity interval training (HIIT) (D).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole-Body Electromyostimulation Training
Description: The WB-EMS training program consisted of six WB-EMS training sessions (one per week) and six running training sessions (also one per week).~This intervention programme followed a within-day undulating periodization model. The training sessions were divided into four parts: warm up (A), strength (B), high intensity interval power training (c), and high intensity interval training (HIIT) (D).
Study: NCT03359590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg
Description: The treatment consists of sitagliptin tablets (100 mg/day) for up to 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The treatment consists of placebo tablets for up to 24 weeks.
Study: NCT04226833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entrectinib
Description: 1x100 milligram (mg) capsule given with approximately 240 milliliter (mL) of water within 30 minutes of consumption of a standardized meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entrectinib
Description: 1x100 milligram (mg) capsule given with approximately 240 milliliter (mL) of water within 30 minutes of consumption of a standardized meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entrectinib
Description: 1x100 milligram (mg) capsule given with approximately 240 milliliter (mL) of water within 30 minutes of consumption of a standardized meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entrectinib
Description: 1x100 milligram (mg) capsule given with approximately 240 milliliter (mL) of water within 30 minutes of consumption of a standardized meal
Study: NCT04399122

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetaminophen/codeine vs acetaminophen/oxycodone
Description: pain medications

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetaminophen/codeine vs acetaminophen/oxycodone
Description: pain medications
Study: NCT03358511

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Primal Defense Ultra® Probiotic Formula is an over-the-counter probiotic that provides 15 billion colony forming units of 13 species of beneficial bacteria, including Saccharomyces boulardii, Lactobacillus plantarum, Bacillus subtilis, Bifidobacterium lactis, Bifidobacterium bifidum, Lactobacillus rhamnosus, Bifidobacterium breve, lactobacillus casei, Lactobacillus salivarius, Lactobacillus acidophilus, Lactobacillus brevis, Bifidobacterium longum, and Lactobacillus paracasei.
Study: NCT02701738

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Overeating Protocol
Description: Subjects will ingest 30% more calories per day than their calculated daily energy requirements (\~750kcals extra energy intake each day). All subjects will be instructed (and will be guided) to consume a diet containing approximately 50% carbohydrate, 35% fat, and 15% protein.
Study: NCT04441112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Intraarticular Injection
Description: Injections will be given under ultrasound guidance with one of two possible medications.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Intraarticular Injection
Description: Injections will be given under ultrasound guidance with one of two possible medications.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Intraarticular Injection
Description: Injections will be given under ultrasound guidance with one of two possible medications.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Intraarticular Injection
Description: Injections will be given under ultrasound guidance with one of two possible medications.
Study: NCT01104142

Intervention type: DEVICE
Intervention: CGM
Description: Continuous Glucose Monitoring System

Intervention type: DEVICE
Intervention: CGM
Description: Continuous Glucose Monitoring System
Study: NCT04537169

Intervention type: PROCEDURE
Intervention: Levator resection
Description: Eyelid crease incision Dissection of the levator aponeurosis to the level of Whitnall ligament. Assessment of the structure of Whitnal ligament. Resection of a calculated part of the aponsurosis. re-attachment of the aponeurosis to the tarsus Incision closure with crease formation

Intervention type: PROCEDURE
Intervention: Levator resection
Description: Eyelid crease incision Dissection of the levator aponeurosis to the level of Whitnall ligament. Assessment of the structure of Whitnal ligament. Resection of a calculated part of the aponsurosis. re-attachment of the aponeurosis to the tarsus Incision closure with crease formation

Intervention type: PROCEDURE
Intervention: Levator resection
Description: Eyelid crease incision Dissection of the levator aponeurosis to the level of Whitnall ligament. Assessment of the structure of Whitnal ligament. Resection of a calculated part of the aponsurosis. re-attachment of the aponeurosis to the tarsus Incision closure with crease formation
Study: NCT02067182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran
Description: * Antral pulmonary vein ablation for patients with AF~* left atrial fibrosis/electrical scar assessment by electroanatomical mapping~* followed by 6 months OAC (3 months blanking period + 3 months observation period)~* in case of AF-recurrence in month 4-6: re- pulmonary vein ablation~* followed again by 6 months OAC (3 months blanking period + 3 months observation period)~AF-free patients as assessed by 72h Holter ECG and symptoms wil be random-izedals to the following two interventional arms:~* Experimental arm (group A): OAC with dabigatran for 12 months~* Control arm (group B): No OAC (no placebo medication) for 12 months - Cerebral MRI at randomisation and 12 months later
Study: NCT00860821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8309
Description: oral solution 30 mg/g, dose: 300mg bid for 3 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AZD8309
Description: oral solution 30 mg/g, dose: 300mg bid for 3 days
Study: NCT00723879

Intervention type: BIOLOGICAL
Intervention: Peginterferon alfa-2b (SCH 54031)
Description: Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.

Intervention type: DRUG
Intervention: Ribavirin (SCH 18908)
Description: Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.

Intervention type: BEHAVIORAL
Intervention: Patient assistance program
Description: Patient assistance programs will be classified as follows:~1. medications, including psychiatric medications (antidepressants);~2. other interventions, including nurse telephone calls and nurse support in the office: and~3. educational literature about hepatitis C containing information about the disease, mode of transmission, complications, and treatment and treatment drawbacks that will be given to each patient at the start of treatment.
Study: NCT01794585

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Based Exercise
Description: A structured, individually tailored, protocol driven, reproducible therapeutic intervention. The study intervention will consist of individually prescribed selections from three off-the-shelf VR games that target the type and severity of balance deficits elicited during the completion of a baseline assessment. Participants randomized to receive this intervention will be assigned a home balance program that utilizes an Xbox Kinect system to provide balance activities.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Exercise
Description: An individualized home balance exercise program that also targets identified balance system-specific deficits, however, utilizes no VR components.
Study: NCT02407522

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Black rice
Description: They asked to keep their normal life style during intervention

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: follow-up
Description: They asked not to consume any black rice or excess amount of food rich in anthocyanin compared to their normal life style, such as grapes, blueberry, red wine, black bean during intervention.
Study: NCT00695617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trisodiumcitrate
Description: trisodiumcitrate 1.035 M

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trisodiumcitrate
Description: trisodiumcitrate 1.035 M
Study: NCT04300582

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac catheterization standard strategy
Description: Cardiac catheterization by forearm approach 3 to 24 hours after thrombolytic completion in STEMI patients

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac catheterization fast strategy
Description: Cardiac catheterization by forearm approach within 3 hours after thrombolytic completion in STEMI patients
Study: NCT02791672

Intervention type: BEHAVIORAL
Intervention: Discharge within 24 hours
Description: If both the physician and patient have no concerns within 24 hours of a Latissimus Dorsi Flap breast reconstruction the patient will be discharged home and enrolled in the cohort group.
Study: NCT00555555

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alphanate SD/HT
Description: A general guideline based on the product Full Prescribing Information is recommended with a maximum dose of 80 VWF:RCof IU/kg. The number of administrations before, during, and after the surgery procedure depends on the subject's clinical condition and the type of surgery itself. Single administrations or multiple doses may be appropriate. The dose of Alphanate® administered to each subject will be recorded as IU of VWF:RCof and also as IU of FVIII:C. The lot number for each vial of concentrate administered will also be recorded.
Study: NCT00611195

Intervention type: DRUG
Group type: OTHER
Intervention: propofol, remifentanil
Description: propofol 3micrgr/ml (TCI plasma concentration Kataria model) versus propofol 3micrgr/ml and remifentanil 0.05microgr/kg/min
Study: NCT02400450

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Functional Ingredient Group
Description: Participants will be provided with a mix of 6 study products to use over the 12 week trial (2 per day). These will be a) oatmeal, b) pancake mix, c) chocolate crunch bar, d) cranberry nut bar, e) anytime sprinkle, and f) smoothie mix, standardized for the content of functional ingredients.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control Ingredient Group
Description: The control group will receive a comparable set of food items to use over the 12 week trial (2 per day). These food items will contain an equivalent amount of calories per portion but without the additional functional ingredients.
Study: NCT02743416

Intervention type: OTHER
Intervention: ECG screening (Zenicor-ECG) for atrial fibrillation
Description: Determination of the biomarker NT-proBNP together with single-lead ECG screening for silent atrial fibrillation.
Study: NCT02414724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Given PO
Study: NCT00726934

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Food Safety Guidelines
Description: Participants will be randomized to the food safety guidelines will receive information and recommendations regarding Food Shopping, Food Storage, Food Preparation, Safe Cooking, and Safe Serving of Food.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Food Safety Guidelines
Description: Participants will be randomized to the food safety guidelines will receive information and recommendations regarding Food Shopping, Food Storage, Food Preparation, Safe Cooking, and Safe Serving of Food.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neutropenic Diet
Description: The Neutropenic Diet Guideline includes all information contained in the FDA Food Safety Guidelines with the addition of the following recommendations:~1. Avoid raw vegetables and fruit (Oranges and bananas are okay.)~2. Avoid take-out foods and fast foods and fountain drinks.~3. Avoid aged cheese (blue, Roquefort, Brie).~4. Cook all produce to well done. Eggs must be hard-boiled.~5. Avoid deli meats.~6. No raw nuts, nuts roasted in shell, or freshly ground nut butters from a health food store.~7. No well water~8. No yogurt
Study: NCT04029961

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Video Education
Description: Prior to their CT simulation, participants will receive education on radiation therapy in the form of a video.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR-based Education
Description: Prior to their CT simulation, participants will receive education on radiation therapy in the form of an immersive VR program delivered through a head-mounted display (HMD).
Study: NCT02992483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIK665
Description: MIK665
Study: NCT05186025

Intervention type: DRUG
Intervention: MATA trees or MATA grass
Description: Glutaraldehyde-modified and MCT® (MicroCrystalline Tyrosine)-adsorbed allergoids

Intervention type: DRUG
Intervention: MATA trees or MATA grass
Description: Glutaraldehyde-modified and MCT® (MicroCrystalline Tyrosine)-adsorbed allergoids
Study: NCT03082131

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resistant Starch Wheat
Description: The investigators will be testing high amylose wheat varieties developed by Arcadia Biosciences that have high levels of RS in the endosperm, the source of refined flour. Compared to regular wheat varieties with RS levels of less than 1%, Arcadia's wheat varieties contain between 16% and 34% RS.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resistant Starch Wheat
Description: The investigators will be testing high amylose wheat varieties developed by Arcadia Biosciences that have high levels of RS in the endosperm, the source of refined flour. Compared to regular wheat varieties with RS levels of less than 1%, Arcadia's wheat varieties contain between 16% and 34% RS.
Study: NCT02749448

Intervention type: OTHER
Group type: OTHER
Intervention: mesenchymal stem cell
Description: There are complex sets of non-hematopoietic cells in bone marrow called mesenchymal progenitor cells (MPCs). MSCs are well-known as multipotent cells that have the ability to self-renew and differentiate into a great variety of cells. MSCs can be isolated from bone marrow, umbilical cord, peripheral blood and adipose tissue, and cultured in specific media. MSC colony formation, which is known as marrow-like stromal cells and MPCs, is similar to fibroblast colony forming unit (CFU-F) in in vitro condition. According to the International Society for Cellular Therapy (ISCT), MSCs can be easily detected or identified from other cells using flow cytometric analysis to detect specific surface markers
Study: NCT00231569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 301012 or Placebo
Description: 30 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, and 29

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 301012 or Placebo
Description: 100 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, and 29

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 301012 or Placebo
Description: 200 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, and 29

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 301012 or Placebo
Description: 300 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, and 29

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 301012 or Placebo
Description: 400 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, and 29

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 301012 or Placebo
Description: 200 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, and 85

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 301012 or Placebo
Description: 300 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, and 85
Study: NCT02023255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39393406
Description: In Part A of the study, participants will receive single dose of JNJ-39393406 50 mg, 150 mg, 450 mg, 1,350 mg, and 2,700 mg once daily for 7 consecutive days. In Part B of the study, participants will receive single dose of JNJ-39393406 based on the PK data from Part A of the study once daily for 13 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39393406
Description: In Part A of the study, participants will receive single dose of JNJ-39393406 50 mg, 150 mg, 450 mg, 1,350 mg, and 2,700 mg once daily for 7 consecutive days. In Part B of the study, participants will receive single dose of JNJ-39393406 based on the PK data from Part A of the study once daily for 13 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39393406
Description: In Part A of the study, participants will receive single dose of JNJ-39393406 50 mg, 150 mg, 450 mg, 1,350 mg, and 2,700 mg once daily for 7 consecutive days. In Part B of the study, participants will receive single dose of JNJ-39393406 based on the PK data from Part A of the study once daily for 13 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39393406
Description: In Part A of the study, participants will receive single dose of JNJ-39393406 50 mg, 150 mg, 450 mg, 1,350 mg, and 2,700 mg once daily for 7 consecutive days. In Part B of the study, participants will receive single dose of JNJ-39393406 based on the PK data from Part A of the study once daily for 13 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39393406
Description: In Part A of the study, participants will receive single dose of JNJ-39393406 50 mg, 150 mg, 450 mg, 1,350 mg, and 2,700 mg once daily for 7 consecutive days. In Part B of the study, participants will receive single dose of JNJ-39393406 based on the PK data from Part A of the study once daily for 13 consecutive days.
Study: NCT02061410

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimlation (NMES)
Description: The intervention was performed with subjects seated on a regular chair (hip and knee angles maintained at approximately 908), 3 times/week for a period of 8 weeks. NMES parameters included: rectangular biphasic symmetric current, pulse duration of 400 ms and stimulation frequency of 80 Hz.
Study: NCT04005131

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot and tDCS on-line
Description: Combined transcranial direct current stimulation(tDCS) on-line and upper extremity rehabilitation robot for 5 times a week for 10 weeks
Study: NCT05255120

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intiensified structured perioperative information
Description: The doctor takes a medical history and examines the patient according to regular routines, but uses the algorithm as support in deciding on the surgical method. After the doctor's visit, the patient must see a research nurse to receive the intensified preoperative information about hysterectomy. This information is designed according to a checklist. The patient can also download a mobile application. The study-specific mobile application (app) contains information about hysterectomy. The information is structured in three parts - Before the Operation, At the Hospital and After the Operation. A timeline describes the activities and events that occur before, around and after the operation. Within each section there are several information links, with eg checklists.
Study: NCT03588507

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: PPF+NCHA bone graft substitute
Description: nanocrystalline hydroxyapatite bone graft is a a newly developed HA containing about 65% water and 35% nanostructured apatite particles. This gave the nanocrystalline hydroxyapatite bone graft many advantages such as providing a close contact with the surrounding tissues, bioresorbability and extremely high number of nano-sized particles and molecules on the surface .
Study: NCT01689220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-02L (darinaparsin for injection)
Description: Cohort 1: Darinaparsin 300 mg/m2 for 5 consecutive days every 28 days (5 days therapy, 23 days no therapy is one cycle). Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-02L (darinaparsin for injection)
Description: Cohort 2: Darinaparsin 300 mg/m2 for 5 consecutive days every 21 days (5 days therapy, 16 days no therapy is one cycle). Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.
Study: NCT02753140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study: NCT01843868

Intervention type: DRUG
Group type: OTHER
Intervention: Standard anti-emetics in conjunction with R-CHOP
Study: NCT05615324

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Talk Preventive Intervention
Description: This is a clinician facilitated, psychoeducational preventive intervention that includes on average 8 sessions designed to improve family communication and understanding of parental mental illness, improve interpersonal relationships, and promote child resilience and utilization of social support. An important tool throughout the intervention is the logbook which the clinician uses for taking notes with each family. The logbook prescribes the planned topics to be covered in each session and the contents of the sessions are noted in the logbook by the clinicians.
Study: NCT03029169

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propafenone i.v.
Description: Treatment